Compare J M Smucker Co (SJM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Viatris Inc — how do they compare? J M Smucker Co trades at $112.69 (market cap $11.97B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and J M Smucker Co pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| SJM | VTRS | |
|---|---|---|
Market Cap | $11.97B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $117.05 | $17.39 |
52-Week Low | $89.53 | $8.74 |
Enterprise Value | $19.00B | $32.00B |
Dividend Yield | 3.93% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
